Evidence map›Paper›PMID 28557340›Full record

ArticleMolecular oncology2017

TrkA is a binding partner of NPM-ALK that promotes the survival of ALK

Wenyu Shi, Suraj Konnath George, Bhawana George, Choladda V Curry, Albina Murzabdillaeva, Serhan Alkan, Hesham M Amin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.Journal of experimental & clinical cancer research : CR · 2018
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Wenyu ShiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Suraj Konnath GeorgeDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bhawana GeorgeDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Choladda V CurryDepartment of Pathology and Immunology, Baylor College of Medicine & Texas Children's Hospital, Houston, TX, USA.
Albina MurzabdillaevaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Serhan AlkanDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USCedars-Sinai Medical Center · USTexas Children's Hospital · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA151533
6 · The paper itself

Abstract

Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK

Indexed as

Anaplastic Lymphoma KinaseAnimalsCell Line, TumorCell ProliferationCell SurvivalDown-RegulationHumansLymphoma, T-CellMiceMice, SCIDNerve Growth FactorPhosphorylationProtein BindingProtein Kinase InhibitorsProtein KinasesProtein-Tyrosine KinasesALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseNerve Growth Factorp80(NPM-ALK) proteinProtein Kinase InhibitorsProtein KinasesProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesRNA, Small Interferingtropomyosin kinaseCHOPNGFNPM-ALKT-cell lymphomaTrkA

Identifiers

PMID28557340
PMCPMC5579389
OpenAlexW2616954162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.